Prestige Consumer Healthcare (NYSE:PBH) VP Jeffrey Zerillo Sells 281 Shares

Prestige Consumer Healthcare Inc. (NYSE:PBH) VP Jeffrey Zerillo sold 281 shares of the business’s stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $60.00, for a total transaction of $16,860.00. Following the completion of the sale, the vice president directly owned 42,048 shares of the company’s stock, valued at approximately $2,522,880. The trade was a 0.66% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

Jeffrey Zerillo also recently made the following trade(s):

• On Friday, November 28th, Jeffrey Zerillo sold 719 shares of Prestige Consumer Healthcare stock. The stock was sold at an average price of $60.00, for a total transaction of $43,140.00.

Prestige Consumer Healthcare Stock Performance

Prestige Consumer Healthcare stock traded down $0.13 during midday trading on Tuesday, hitting $59.80. The company’s stock had a trading volume of 611,329 shares, compared to its average volume of 420,579. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.38 and a quick ratio of 2.99. The company has a market cap of $2.88 billion, a price-to-earnings ratio of 14.04, a PEG ratio of 1.93 and a beta of 0.41. Prestige Consumer Healthcare Inc. has a 1-year low of $57.25 and a 1-year high of $90.04. The company has a 50-day moving average price of $61.23 and a two-hundred day moving average price of $70.42.

Prestige Consumer Healthcare (NYSE:PBH) last announced its earnings results on Thursday, November 6th. The company reported $1.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.97 by $0.10. Prestige Consumer Healthcare had a net margin of 19.02% and a return on equity of 12.69%. The firm had revenue of $274.11 million for the quarter, compared to analyst estimates of $257.14 million. During the same quarter in the prior year, the business posted $1.09 EPS. The business’s revenue was down 3.4% compared to the same quarter last year. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.580 EPS. As a group, sell-side analysts predict that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have commented on the company. Oppenheimer lowered their price objective on Prestige Consumer Healthcare from $82.00 to $72.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 21st. Wall Street Zen cut Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a research report on Saturday, August 9th. Canaccord Genuity Group dropped their price target on Prestige Consumer Healthcare from $100.00 to $88.00 and set a “buy” rating for the company in a research note on Friday, November 7th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research report on Wednesday, October 8th. Finally, Jefferies Financial Group decreased their target price on shares of Prestige Consumer Healthcare from $75.00 to $71.00 and set a “hold” rating on the stock in a report on Monday, October 27th. Four investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $85.33.

Hedge Funds Weigh In On Prestige Consumer Healthcare

Institutional investors have recently modified their holdings of the business. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Prestige Consumer Healthcare by 11.3% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 12,304 shares of the company’s stock valued at $1,058,000 after buying an additional 1,251 shares in the last quarter. Jefferies Financial Group Inc. acquired a new position in Prestige Consumer Healthcare during the first quarter worth about $203,000. Blair William & Co. IL lifted its holdings in shares of Prestige Consumer Healthcare by 16.4% in the first quarter. Blair William & Co. IL now owns 106,114 shares of the company’s stock worth $9,123,000 after acquiring an additional 14,967 shares during the last quarter. Costello Asset Management INC bought a new position in shares of Prestige Consumer Healthcare in the first quarter worth about $112,000. Finally, Westwood Holdings Group Inc. boosted its stake in shares of Prestige Consumer Healthcare by 7.1% in the 1st quarter. Westwood Holdings Group Inc. now owns 861,282 shares of the company’s stock valued at $74,044,000 after purchasing an additional 56,802 shares in the last quarter. Institutional investors and hedge funds own 99.95% of the company’s stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.